You are here
Ernő Schaller-Baross
You are viewing a person dossier. From here you can follow this person’s terms, documents, signals and official vote items.
Jump to
Person dossier
Ernő Schaller-Baross
Voting profiles
Note: these are candidate profiles. They show where the data points, but require manual review of the voting context before conclusions are drawn.
Terms
EP term 10
EP term 9
Documents
Targeted, linguistically and culturally accessible mental health support for Hungarian women in Transcarpathia
Training given to the EU diplomatic service by the Muslim Brotherhood network
Concerns about the Commission’s neutrality in elections, given past cases of perceived interference amid Commissioner Virkkunen’s recent statement
ONTWERPRESOLUTIE over de overwinning van de nieuwgekozen president Donald Trump
Trump en Amerikaans rechts
ONTWERPRESOLUTIE over de mogelijkheid voor de lidstaten om niet deel te nemen aan het migratiebeleid van de EU
Violation of the rule of law by the new Polish Government and the Commission’s silence
ONTWERPRESOLUTIE over de rechtsstaat en de gevolgen van het arrest van het HvJ-EU
ONTWERPRESOLUTIE over de schending van het EU-recht en van de rechten van lhbtiq-burgers in Hongarije als gevolg van de door het Hongaarse parlement aangenomen wetswijzigingen
Right of access to documents under Article 42 of the Charter of Fundamental Rights and redacted contracts with vaccine manufacturers
Pfizer en covid
Improving and enforcing the EU Air Passengers Rights Regulation
New due diligence legislative proposal put forward despite the negative opinion of the Regulatory Scrutiny Board
Alleged conflicts of interest and influence-trafficking by judges of the Court of Justice of the European Union and the Commission
Impact of rising energy prices on citizens
Pharmaceutical companies raising EU COVID-19 vaccine prices
Pfizer en covid
The EU Digital COVID Certificate and the Erasmus+ programme
Pfizer en covid
Transparency and accountability in the procurement of COVID-19 vaccines
Pfizer en covid
EU response to the impact of the COVID-19 pandemic on small and medium-sized enterprises
Pfizer en covid
Commission’s standpoint on non-governmental organisations willfully breaking the law
Supporting layers Provenance and audit + Signals
Provenance and audit
This block makes visible which source layer and datapoints the current view is based on.
Signals
No signal clusters found for this topic yet.
Official vote items Votes and seat distribution
Official vote items
A10-0121/2026 – Isabella Lövin – Motion for a resolution (as a whole)
A10-0121/2026 – Isabella Lövin – Recital AY – Am 7
A10-0121/2026 – Isabella Lövin – Recital Y – Am 6
A10-0121/2026 – Isabella Lövin – Recital A – Am 13
A10-0121/2026 – Isabella Lövin – § 56/2
A10-0121/2026 – Isabella Lövin – § 56/1
A10-0121/2026 – Isabella Lövin – § 56 – Am 43
A10-0121/2026 – Isabella Lövin – § 55 – Am 42D
A10-0121/2026 – Isabella Lövin – § 43 – Am 12
A10-0121/2026 – Isabella Lövin – § 40
A10-0121/2026 – Isabella Lövin – § 37
A10-0121/2026 – Isabella Lövin – After § 36 – Am 5/2
A10-0121/2026 – Isabella Lövin – After § 36 – Am 5/1
A10-0121/2026 – Isabella Lövin – After § 36 – Am 4
A10-0121/2026 – Isabella Lövin – After § 36 – Am 3
A10-0121/2026 – Isabella Lövin – After § 36 – Am 2
A10-0121/2026 – Isabella Lövin – After § 36 – Am 1
A10-0121/2026 – Isabella Lövin – § 35
A10-0121/2026 – Isabella Lövin – § 22 – Am 36
A10-0121/2026 – Isabella Lövin – § 21 – Am 35
A10-0121/2026 – Isabella Lövin – § 18 – Am 34D
A10-0121/2026 – Isabella Lövin – § 9/2
A10-0121/2026 – Isabella Lövin – § 9/1
A10-0121/2026 – Isabella Lövin – § 9 – Am 30D
A10-0121/2026 – Isabella Lövin – § 8 – Am 29D
A10-0121/2026 – Isabella Lövin – § 6 – Am 27
A10-0121/2026 – Isabella Lövin – § 3 – Am 25
A9-0157/2024 – Javier Zarzalejos, Lucia Yar – Provisional agreement – Am 136
A10-0139/2026 – Jens Gieseke – Decision to enter into interinstitutional negotiations
A10-0137/2026 – Ralf Seekatz – Decision to enter into interinstitutional negotiations
Next logical step
Use these routes to continue your research from this page.